BridgeBio Pharma reports beneficial ownership by Neil Kumar of 9,282,982 shares of Common Stock. That ownership represents 4.6% of the class based on 195,707,702 shares outstanding as of March 31, 2026. The filing breaks the total into direct holdings, exercisable options, restricted stock units vesting within 60 days, and shares held in trusts.
The filing lists 3,903,183 options exercisable within 60 days and 71,215 RSUs vesting within 60 days, plus trust-held shares totaling 5,074,133 that give shared voting/dispositive power.
Positive
None.
Negative
None.
Insights
Neil Kumar holds 9,282,982 shares (4.6%) including options and trust holdings.
The filing itemizes beneficial ownership as 9,282,982 shares, derived from direct holdings, 3,903,183 options exercisable within 60 days, 71,215 RSUs vesting within 60 days, and shares held in two family trusts. It reports voting and dispositive power split between sole and shared authorities.
These details clarify ownership posture and potential near-term exercise/vesting activity; subsequent Form 4s would show any option exercises or open-market transactions.
Key Figures
Beneficially owned:9,282,982 sharesPercent of class:4.6%Shares outstanding:195,707,702 shares+4 more
Percent of class4.6%Based on shares outstanding as of March 31, 2026
Shares outstanding195,707,702 sharesAs of March 31, 2026 (used for percentage calc.)
Options exercisable3,903,183 sharesOptions exercisable within 60 days of March 31, 2026
RSUs vesting71,215 sharesRSUs vesting and settleable within 60 days of March 31, 2026
Sole voting power4,208,849 sharesShares with sole voting power reported
Shared voting power / trust holdings5,074,133 sharesShared voting/dispositive power, including trust-held shares
Key Terms
beneficially owned, exercisable within 60 days, restricted stock units, sole voting power
4 terms
beneficially ownedfinancial
"Amount beneficially owned: 9,282,982 shares of Common Stock"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
exercisable within 60 daysregulatory
"3,903,183 shares of Common Stock issuable... exercisable within 60 days"
restricted stock unitsfinancial
"71,215 shares of Common Stock issuable... upon the vesting and settlement of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
sole voting powergovernance
"Sole power to vote or to direct the vote: 4,208,849"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
How many BridgeBio (BBIO) shares does Neil Kumar beneficially own?
Neil Kumar beneficially owns 9,282,982 shares of Common Stock. This total includes direct holdings, options exercisable within 60 days, RSUs vesting within 60 days, and shares held in family trusts.
What percentage of BBIO does Neil Kumar own?
Neil Kumar's stake represents 4.6% of the class. The percentage is calculated using 195,707,702 shares outstanding as of March 31, 2026 combined with exercisable options and vesting RSUs.
How many options and RSUs are included in Neil Kumar's filing?
The filing lists 3,903,183 stock options exercisable within 60 days and 71,215 restricted stock units vesting within 60 days. Both are treated as outstanding for percentage calculation under SEC rules.
What voting and dispositive powers does Neil Kumar have at BBIO?
Neil Kumar has sole voting power and sole dispositive power over 4,208,849 shares, and shared voting and shared dispositive power over 5,074,133 shares, as reported in the filing.
Are any BridgeBio shares held in trusts according to the filing?
Yes. The filing reports 4,438,447 shares held by the Kumar Haldea Revocable Trust and 635,686 shares held by the Kumar Haldea Family Irrevocable Trust, with Dr. Kumar listed as co-trustee.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 6)
BridgeBio Pharma, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
10806X102
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
10806X102
1
Names of Reporting Persons
NEIL KUMAR
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
4,208,849.00
6
Shared Voting Power
5,074,133.00
7
Sole Dispositive Power
4,208,849.00
8
Shared Dispositive Power
5,074,133.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
9,282,982.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.6 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: (1) Consists of (i) 234,451 shares of Common Stock held directly by Dr. Kumar, (ii) 3,903,183 shares of Common Stock issuable to Dr. Kumar upon the exercise of stock options exercisable within 60 days of March 31, 2026, (iii) 71,215 shares of Common Stock issuable to Dr. Kumar upon the vesting and settlement of restricted stock units within 60 days of March 31, 2026, (iv) 4,438,447 shares of Common Stock held by the Kumar Haldea Revocable Trust, of which Dr. Kumar is a co-trustee and (v) 635,686 shares of Common Stock held by the Kumar Haldea Family Irrevocable Trust, of which Dr. Kumar is a co-trustee.
(2) Percentage ownership is based on (i) 195,707,702 shares of Common Stock outstanding as of March 31, 2026, (ii) 3,903,183 shares of Common Stock underlying stock options held by Dr. Kumar that are exercisable within 60 days of March 31, 2026 and are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i) and (iii) 71,215 shares of Common Stock underlying restricted stock units held by Dr. Kumar that are subject to vesting and settlement within 60 days of March 31, 2026 and are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i).
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
BridgeBio Pharma, Inc.
(b)
Address of issuer's principal executive offices:
3160 Porter Street, Suite 250, Palo Alto, California, 94304
Item 2.
(a)
Name of person filing:
NEIL KUMAR
(b)
Address or principal business office or, if none, residence:
3160 Porter Street, Suite 250, Palo Alto, California 94304
(c)
Citizenship:
U.S.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP No.:
10806X102
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
9,282,982 shares of Common Stock, which represents (i) 234,451 shares of Common Stock held of record by Dr. Kumar, (ii) 3,903,183 shares of Common Stock issuable to Dr. Kumar upon the exercise of stock options exercisable within 60 days of March 31, 2026, (iii) 71,215 shares of Common Stock issuable to Dr. Kumar upon the vesting and settlement of restricted stock units within 60 days of March 31, 2026, (iv) 4,438,447 shares of Common Stock held of record by Kumar Haldea Revocable Trust and (v) 635,686 shares of Common Stock held of record by the Kumar Haldea Family Irrevocable Trust.
(b)
Percent of class:
4.6%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
4,208,849
(ii) Shared power to vote or to direct the vote:
5,074,133
(iii) Sole power to dispose or to direct the disposition of:
4,208,849
(iv) Shared power to dispose or to direct the disposition of:
5,074,133
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
